{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:19:14Z","timestamp":1793909954877,"version":"4.8.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016290","name":"Insamlingsstiftelsen Cancer- och Allergifonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>PD-1 and PD-L1 are crucial regulators of immunity expressed on the surface of T cells and tumour cells, respectively. Cancer cells frequently use PD-1\/PD-L1 to evade immune detection; hence, blocking them exposes tumours to be attacked by activated T cells. The synergy of PD-1\/PD-L1 blockade with type I interferon (IFN) can improve cancer treatment efficacy. Type I IFN activates immune cells boosts antigen presentation and controls proliferation. In addition, type I IFN increases tumour cell sensitivity to the blockade. Combining the two therapies increases tumoral T cell infiltration and activation within tumours, and stimulate the generation of memory T cells, leading to prolonged patient survival. However, limitations include heterogeneous responses, the need for biomarkers to predict and monitor outcomes, and adverse effects and toxicity. Although treatment resistance remains an obstacle, the combined therapeutic efficacy of IFN\u03b1\/\u03b2 and PD-1\/PD-L1 blockade demonstrated considerable benefits across a spectrum of cancer types, notably in melanoma. Overall, the phases I and II clinical trials have demonstrated safety and efficiency. In future, further investigations in clinical trials phases III and IV are essential to compare this combinatorial treatment with standard treatment and assess long-term side effects in patients.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1249330","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:36:59Z","timestamp":1692902219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Ali","family":"Razaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Durand-Dubief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Bj\u00f6rnstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17090","article-title":"Phase I study of nivolumab combined with IFN-beta for patients with advanced melanoma","volume":"8","author":"Fujimura","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/ol.2022.13355","article-title":"Interferon-alpha and its effects on cancer cell apoptosis","volume":"24","author":"Shi","year":"2022","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2021.08.004","article-title":"Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy","volume":"23","author":"Razaghi","year":"2021","journal-title":"Neoplasia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discovery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219829","article-title":"Empowering therapeutic antibodies with IFN-alpha for cancer immunotherapy","volume":"14","author":"Guo","year":"2019","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFNalpha to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03207.x","article-title":"Perilesional treatment of metastatic melanoma with interferon-beta","volume":"34","author":"Fujimura","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1047584","article-title":"Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages","volume":"4","author":"Kakizaki","year":"2015","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-alpha has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.celrep.2019.07.059","article-title":"Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma","volume":"28","author":"Burrack","year":"2019","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-016-0281-6","article-title":"Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells","volume":"7","author":"Yang","year":"2016","journal-title":"Protein Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1980","article-title":"Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments","volume":"78","author":"Cauwels","year":"2018","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1398876","article-title":"A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment","volume":"7","author":"Cauwels","year":"2018","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02129","article-title":"Interferon-alpha up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling","volume":"9","author":"Bazhin","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.04.017","article-title":"Interferon beta and anti-PD-1\/PD-L1 checkpoint blockade cooperate in NK cell-mediated killing of nasopharyngeal carcinoma cells","volume":"12","author":"Makowska","year":"2019","journal-title":"Transl Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-\u03b12b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"JCO1800632","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II study of pembrolizumab and pegylated-interferon Alfa-2b in advanced melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4301","article-title":"Neoadjuvant pembrolizumab and high-dose IFNalpha-2b in resectable regionally advanced melanoma","volume":"27","author":"Najjar","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675873","article-title":"Prior therapy with pegylated-interferon Alfa-2b improves the efficacy of adjuvant pembrolizumab in resectable advanced melanoma","volume":"11","author":"Jia","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: A joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1417721","article-title":"Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors","volume":"7","author":"Chen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040617","article-title":"IFN-alpha-mediated differentiation of dendritic cells for cancer immunotherapy: advances and perspectives","volume":"8","author":"Lapenta","year":"2020","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1249330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:37:02Z","timestamp":1692902222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1249330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2023.1249330"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1249330","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"article-number":"1249330"}}